Ishfaque Ahmed

Ishfaque Ahmed

Auto-generated profile, based on publicly available information

Ishfaque Ahmed

Sindh Infectious Diseases Hospital and Research Center, Dow University of Health Sciences, Karachi 75100, Pakistan

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2005 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
STSantosh K Tiwari
Santosh K Tiwari
AKAleem Khan
Aleem Khan
KAKhaja S Ahmed
Khaja S Ahmed
SAS Mahaboob Ali
S Mahaboob Ali
IAIrshad Ahmed
Irshad Ahmed
CHChittoor M Habibullah
Chittoor M Habibullah

7 October 2025 in Infectious Medicine
Verified
Journal Article
Open access
UAuzair Abbas
uzair Abbas
HKHarendra Kumar
Harendra Kumar
NHNiaz Hussain
Niaz Hussain
IAIshfaque Ahmed
Ishfaque Ahmed
RLRabeel Nawaz Laghari
Rabeel Nawaz Laghari
MKMahtab Khan
Mahtab Khan
• In this review, we have summarized how chronic hyperglycemia impacts immunity against pathogens. • This review summarizes the immune modulation in diabetes mellitus including immunogenetics of diabetic population. • This review shows how immune modulation in diabetes mellitus impacts the susceptibility of getting infections like tuberculosis, COVID-19 and HIV and the outcome of these infections. • This will help in understanding the phenotype of infections in diabetic population and formulate a different patient care specially in high endemic countries.

7 February 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
MSMuneeba Ahsan Sayeed
Muneeba Ahsan Sayeed
ESElisha Shalim
Elisha Shalim
SFShaiza Farman
Shaiza Farman
FFFizza Farooqui
Fizza Farooqui
BSBeenish Syed
Beenish Syed
MQMuhammad Saeed Quraishy
Muhammad Saeed Quraishy
Background: Each coronavirus disease 2019 (COVID-19) wave is unique in its clinical presentation and outcome. In this study, we compared the clinical characteristics and outcomes of COVID waves 2–5 in inpatient settings. Methods: A retrospective study was conducted at the Sindh Infectious Diseases Hospital and Research Center on adult patients who were admitted with a positive COVID polymerase chain reaction from July 2020 to March 2022. SPSS 26 was used to analyze the data. Results: A total of 3190 COVID-19 patients were admitted. Wave 2 had the highest percentage of discharges compared with mortality (81%; P = .0001). Cytokine release syndrome was most common in wave 3 (32.7%; P = .0001). Severe COVID on admission was predominant in wave 4 (79.4%; P = .0001), with the highest rates of intubation (27.1%; P = .0001), septic shock (24.3%; P = .0001), and disease progression (50.8%; P = .0001). In wave 5, the majority were elderly (median age, 68 years) and had mild COVID (22.4%; P = .0001), most had comorbidities (84.6%; P = .0001), and the ratio of acute kidney injury was high (29.2%; P = .0001). Mortality was lowest in wave 2 (18.9%; P = .0001) and highest in wave 4 (42.5%; P = .0001; odds ratio, 3.18; 95% CI, 2.6–3.8; compared with wave 2). Conclusions: Each wave had some unique characteristics compared with other waves, with wave 4, driven by the Delta variant, being the deadliest one in terms of disease severity and outcomes.